Safety and Efficacy of Dupilumab for the Treatment of Hospitalized Patients With Moderate to Severe Coronavirus Disease 2019: A Phase 2a Trial is a research paper published in Open Forum Infectious Diseases (2022). On theSindex it has a DataRank of 1.1. It has been cited 28 times, with 23 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.505
From this paper's citation signal
Citation Network Contribution
0.622
From 18 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 23 citers.
National Institutes of Health
Grant: R01 AI124214
National Institutes of Health
Grant: T32 AI007496
National Institutes of Health
Grant: T32 DK072922/TL1
National Institutes of Health
Grant: DK132771
National Institutes of Health
Grant: UL1TR003015
National Institutes of Health
Grant: KL2TR003016
National Cancer Institute
Grant: 75N91019D00024
National Institutes of Health
Grant: 3T32DK072922-08S1
Kidney Disease and Inflammation
National Institutes of Health
Grant: 1KL2TR003016-01
Institutional Career Development Core
National Institutes of Health
Grant: 2R01AI124214-06
Role of Type 2 Immunity in Innate Protection from C. difficile
National Institutes of Health
Grant: 5T32AI007496-27
Interdisciplinary Training Program in Immunology
National Institutes of Health
Grant: 5TL1DK132771-05
IGNITE KUH NRSA Training Core
National Institutes of Health
Grant: 3UL1TR003015-03S1
The integrated Translational Health Research Institute of Virginia (iTHRIV): Using Data to Improve Health
Fields of Study
Keywords
Sustainable Development Goals